Skip to main navigation Skip to search Skip to main content

A phase 2 multicenter randomized double blind placebo controlled study to evaluate efficacy, safety, tolerability and pharmacokinetics of Budigalimab and/or ABBV-382

Project: Research

Project Details

StatusFinished
Effective start/end date10/31/23 → 06/30/26

Funding

  • AbbVie Incorporated: $247,403.64